LEADER 03031nam 2200877z- 450 001 9910557107203321 005 20210501 035 $a(CKB)5400000000040975 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/69370 035 $a(oapen)doab69370 035 $a(EXLCZ)995400000000040975 100 $a20202105d2020 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 00$amTOR Signaling in Metabolism and Cancer 210 $aBasel, Switzerland$cMDPI - Multidisciplinary Digital Publishing Institute$d2020 215 $a1 online resource (204 p.) 311 08$a3-03943-553-1 311 08$a3-03943-554-X 330 $aThe mechanistic/mammalian target of rapamycin (mTOR), a serine/threonine kinase, is a central regulator for human physiological activity. Deregulated mTOR signaling is implicated in a variety of disorders, such as cancer, obesity, diabetes, and neurodegenerative diseases. The papers published in this Special Issue summarize the current understanding of the mTOR pathway and its role in the regulation of tissue regeneration, regulatory T cell differentiation and function, and different types of cancer including hematologic malignancies, skin, prostate, breast, and head and neck cancer. The findings highlight that targeting mTOR pathway is a promising strategy to fight against certain human diseases. 606 $aMedicine$2bicssc 610 $aAcute Lymphoblastic leukemia 610 $aadhesion 610 $aAkt 610 $abasal cell carcinoma 610 $abiomarkers 610 $acancers 610 $acell metabolism 610 $acell signalling 610 $aclinical trials 610 $acombination 610 $aeribulin 610 $aeverolimus 610 $aFoxp3 610 $ahead and neck cancer 610 $ahematologic malignancies 610 $ahistone deacetylase 610 $ainhibitors 610 $aintegrins 610 $aintestine 610 $ainvasion 610 $aliver 610 $amelanoma 610 $aMerkel cell carcinoma 610 $ametabolism 610 $amTOR 610 $amTOR signaling 610 $amTOR signalling 610 $amuscle 610 $amutant genes 610 $aneuron 610 $aphotodynamic therapy 610 $aphytochemicals 610 $aPI3K 610 $aPI3K/AKT/mTOR 610 $aprostate cancer 610 $aregulatory T cells 610 $askin cancers 610 $asquamous cell carcinoma 610 $asynergy 610 $aT cells 610 $atargeted therapies 610 $atargeted therapy 610 $atissue regeneration 610 $aTNBC 610 $atumor 615 7$aMedicine 700 $aHuang$b Shile$4edt$01325337 702 $aHuang$b Shile$4oth 906 $aBOOK 912 $a9910557107203321 996 $aMTOR Signaling in Metabolism and Cancer$93036762 997 $aUNINA LEADER 01752nam 2200409z- 450 001 9910493731303321 005 20210817 035 $a(CKB)5590000000537509 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/71664 035 $a(oapen)doab71664 035 $a(EXLCZ)995590000000537509 100 $a20202108d2020 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 00$aCase-Based Decision Support for Disaster Management 210 $aKarlsruhe$cKIT Scientific Publishing$d2020 215 $a1 online resource (322 p.) 311 08$a3-7315-0992-X 330 $aDisasters are characterized by severe disruptions of the society's functionality and adverse impacts on humans, the environment, and economy that cannot be coped with by society using its own resources. This work presents a decision support method that identifies appropriate measures for protecting the public in the course of a nuclear accident. The method particularly considers the issue of uncertainty in decision-making as well as the structured integration of experience and expert knowledge. 606 $aEconomics$2bicssc 610 $acase-based reasoning 610 $adecision support 610 $adisaster management 610 $aEntscheidungsunterstu?tzung 610 $aFallbasiertes Schließen 610 $aKatastrophenmanagement 610 $anuclear emergency management 610 $anuklearer Notfallschutz 615 7$aEconomics 700 $aMöhrle$b Stella$4auth$01280548 906 $aBOOK 912 $a9910493731303321 996 $aCase-Based Decision Support for Disaster Management$93017197 997 $aUNINA